Future Cardiol. 2012;8(4):647-670. Clarifying the relationship between anthracycline dosages and the corresponding degree of cardiotoxicity is continuously challenging. Clinically significant cardiac ...
SNP-SNP interactions and a 4-locus model for prediction the risk of anthracycline-mediated cardiotoxicity in patients with breast cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
TBCRC 050: A phase 1b/2 trial of niraparib and trastuzumab in HER2-positive metastatic breast cancer (MBC): Efficacy and correlative analyses. HER2-targeted tyrosine kinase inhibitors in breast cancer ...
Individual anthracycline dose Higher individual anthracycline doses are associated with increased late cardiotoxicity, even when cumulative doses are limited [54,60] Type of anthracycline Liposomal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results